| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 74.1 | 49.3 |
| Gross profit | 16.8 | 10.7 |
| Profit before tax | -7.6 | -9.7 |
| Net income | -7.6 | 57.4 |
| EPS (diluted, $ a share) | $-0.09 | $0.70 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +50.3% |
|---|---|
| Gross margin | 22.7% |
| Operating margin | -5.2% |
10-Q filed with the SEC, NASDAQ: SRTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Strata Critical Medical, Inc.: key numbers
- Share price
- $5.42Close, Nov 16
- Market cap
- $484M
- Shares outstanding
- 89.32MLatest SEC cover page
- Sector
- Energy & Transportation
- Industry
- Transportation ServicesSIC 4700
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Strata Critical Medical, Inc.
All →Strata Critical Medical Earnings Call: Key Takeaways
Strata Critical Medical delivered strong Q3 2026 results with record adjusted EBITDA margins and free cash flow, despite seasonal industry headwinds and regulatory-driven shifts in logistics flight distances.
- Call
- Nov 3, 2026, 8:00 AM ET
Strata Critical Medical Financial Results
Strata Critical Medical reported Q3 2026 financial results with revenue increasing 50.3% year-over-year to $74.1 million, driven by significant growth in its Clinical segment. The company also announced a new $20 million share repurchase authorization to be executed alongside its ongoing M&A strategy.